Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. JAMA Dermatol. 2015;151(10):1081–6.

Article  PubMed  Google Scholar 

Madan V, Lear JT, Szeimies R-M. Non-melanoma skin cancer. The Lancet. 2010;375(9715):673–85.

Article  CAS  Google Scholar 

McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014;50(4):774–83.

Article  PubMed  Google Scholar 

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verkouteren BJ, Wakkee M, Reyners AK, Nelemans P, Aarts MJ, Rácz E, et al. Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study. Br J Cancer. 2021;124(7):1199–206.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldenberg G, Karagiannis T, Palmer JB, Lotya J, O’Neill C, Kisa R, et al. Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: a retrospective cohort study. J Am Acad Dermatol. 2016;75(5):957-66.e2.

Article  PubMed  Google Scholar 

Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib: a syndrome. N Engl J Med. 1960;262(18):908–12.

Article  CAS  PubMed  Google Scholar 

Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hahn H, Christiansen J, Wicking C, Zaphiropoulos PG, Chidambaram A, Gerrard B, et al. A Mammalian patched homolog is expressed in target tissues of sonic hedgehog and maps to a region associated with developmental abnormalities. J Biol Chem. 1996;271(21):12125–8.

Article  CAS  PubMed  Google Scholar 

Gailani MR, Ståhle-Bäckdahl M, Leffell DJ, Glyn M, Zaphiropoulos PG, Undén AB, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996;14(1):78–81.

Article  CAS  PubMed  Google Scholar 

Lum L, Beachy PA. The Hedgehog response network: sensors, switches, and routers. Science. 2004;304(5678):1755–9.

Article  CAS  PubMed  Google Scholar 

Jacobsen AA, Aldahan AS, Hughes OB, Shah VV, Strasswimmer J. Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies. JAMA Dermatol. 2016;152(7):816–24.

Article  PubMed  Google Scholar 

Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332.

Article  PubMed  PubMed Central  Google Scholar 

Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72(6):1021-6.e8.

Article  PubMed  Google Scholar 

Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–28.

Article  CAS  PubMed  Google Scholar 

Dummer R, Guminksi A, Gutzmer R, Lear JT, Lewis KD, Chang ALS, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020;182(6):1369–78.

Article  CAS  PubMed  Google Scholar 

Goldman J, Eckhardt SG, Borad MJ, Curtis KK, Hidalgo M, Calvo E, et al. Phase I dose-escalation trial of the oral investigational hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clin Cancer Res. 2015;21(5):1002–9.

Article  CAS  PubMed  Google Scholar 

Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32(8):745–51.

Article  CAS  PubMed  Google Scholar 

Xie P, Lefrancois P. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(6):1089-100 e17.

Article  CAS  PubMed  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Internal Med. 2009;151(4):264–9.

Article  Google Scholar 

Viscusi KS, Hanke CW. Vismodegib for locally advanced basal cell carcinoma: descriptive analysis of a case series and comparison to the literature. J Drugs Dermatol. 2015;14(9):956–62.

CAS  PubMed  Google Scholar 

Tauber G, Pavlovsky L, Fenig E, Hodak E. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp. J Am Acad Dermatol. 2015;73(5):799–801.

Article  CAS  PubMed  Google Scholar 

Ozgur OK, Yin V, Chou E, Ball S, Kies M, William WN, et al. Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome. Am J Ophthalmol. 2015;160(2):220-7.e2.

Article  CAS  PubMed  Google Scholar 

Sofen H, Gross KG, Goldberg LH, Sharata H, Hamilton TK, Egbert B, et al. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015;73(1):99-105.e1.

Article  CAS  PubMed  Google Scholar 

Demirci H, Worden F, Nelson CC, Elner VM, Kahana A. Efficacy of Vismodegib (Erivedge™) for basal cell carcinoma involving the orbit and periocular area. Ophthalmic Plast Reconstr Surg. 2015;31(6):463.

Article  PubMed  PubMed Central  Google Scholar 

Chang ALS, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day B-M, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60–9.

Article  CAS  PubMed  Google Scholar 

Gill HS, Moscato EE, Chang ALS, Soon S, Silkiss RZ. Vismodegib for periocular and orbital basal cell carcinoma. JAMA Ophthalmol. 2013;131(12):1591–4.

Article  CAS  PubMed  Google Scholar 

Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164–72.

Article  Google Scholar 

Simone PD, Schwarz JM, Strasswimmer JM. Four-year experience with vismodegib hedgehog inhibitor therapy. J Am Acad Dermatol. 2016;74(6):1264–5.

Article  PubMed  Google Scholar 

Basset-Seguin N, Hauschild A, Kunstfeld R, Grob J, Dreno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334–48.

Article  CAS  PubMed  Google Scholar 

Bertrand N, Guerreschi P, Basset-Seguin N, Saiag P, Dupuy A, Dalac-Rat S, et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (VISMONEO study): neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma. EClinicalMedicine. 2021;35: 100844.

Article  PubMed  PubMed Central  Google Scholar 

Kahana A, Unsworth SP, Andrews CA, Chan MP, Bresler SC, Bichakjian CK, et al. Vismodegib for preservation of visual function in patients with advanced periocular basal cell carcinoma: the VISORB trial. Oncologist. 2021;26(7):e1240–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tronconi MC, Solferino A, Giordano L, Borroni R, Mancini L, Santoro A. Tailored toxicity-driven administration of Vismodegib in patients with multiple or locally advanced basal cell carcinoma: a pilot analysis. Front Oncol. 2020;10: 563404.

Article  PubMed  PubMed Central  Google Scholar 

Villani A, Fabbrocini G, Cappello M, Costa C, Scalvenzi M. Real-Life Effectiveness of Vismodegib in patients with metastatic and advanced basal cell carcinoma: characterization of adverse events and assessment of health-related quality of life using the dermatology life quality index (DLQI) test. Dermatol Ther (Heidelb). 2019;9(3):505–10.

Article  PubMed  PubMed Central  Google Scholar 

Xavier C, Lopes E, Bexiga C, Moura C, Gouveia E, Duarte AF. Vismodegib for treatment of periocular basal cell carcinoma—6-year experience from a tertiary cancer center. An Bras Dermatol. 2021;96(6):712–6.

Article  PubMed  PubMed Central  Google Scholar 

Sekulic A, Yoo S, Kudchadkar R, Guillen J, Rogers G, Chang ALS, et al. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry. PLoS ONE. 2022;17(1): e0262151.